What a $227,000 GeneDx Insider Sale Means as Revenue Climbs 17%
Key Points
The CFO of GeneDx reported selling 3,729 Class A shares for a total transaction value of $226,596.87 on June 16, 2026.
The sale represented 8.54% of Feeley's direct Class A common stock holdings, reducing his direct Class A position from 43,683 to 39,954 shares.
This transaction stemmed from the exercise of 7,197 options, with the shares sold directly and no indirect or third-party entity involvement.
- 10 stocks we like better than GeneDx ›
Kevin Feeley, the Chief Financial Officer of GeneDx (NASDAQ:WGS), reported the sale of 3,729 shares of Class A Common Stock for approximately $227,000 on June 16, 2026, following an option exercise and immediate disposition as disclosed in the SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares traded (direct) | 3,729 |
| Transaction value | ~$227,000 |
| Post-transaction Class A shares (direct) | 39,954 |
Transaction value based on SEC Form 4 weighted average purchase price ($60.77); post-transaction value based on June 16, 2026 market close ($60.77).
Key questions
- What is the underlying structure of this transaction regarding options and equity?
The transaction involved exercising 7,197 options, with 3,729 shares immediately sold and the remainder added to direct ownership. - What is Feeley's remaining exposure to GeneDx equity following this sale?
As of June 16, 2026, Feeley holds 39,954 Class A shares directly (~$2.4 million in market value). - Did this transaction materially impact Feeley's ownership or market sentiment?
The sale represented 8.54% of Feeley's direct Class A holdings, and as of June 16, 2026, Feeley directly holds 39,954 Class A shares and retains 21,590 Restricted Stock Units, according to the Form 4; the transaction was routine in nature, associated with equity award vesting rather than discretionary selling.
Company overview
| Metric | Value |
|---|---|
| Market capitalization | $1.65 billion |
| Revenue (TTM) | $442.68 million |
| Net income (TTM) | -$77.81 million |
| 1-year price change | -27% |
* 1-year price change is calculated using June 23, as the reference date.
Company snapshot
- GeneDx offers health intelligence solutions leveraging AI and machine learning on clinical and genomic datasets, primarily via the Centrellis platform.
- The firm generates revenue by providing data-driven, evidence-based healthcare insights and solutions to improve patient outcomes and optimize care pathways.
- It targets healthcare providers, payers, and research institutions seeking advanced analytics for personalized medicine and disease management.
GeneDx operates at scale with a focus on transforming healthcare through advanced data analytics. The company’s strategy centers on harnessing proprietary technology and extensive datasets to deliver actionable insights for personalized health management. Its competitive edge lies in the integration of AI-driven tools with comprehensive clinical and genomic information, positioning it as a leader in the healthcare information services sector.
What this transaction means for investors
This transaction looks almost entirely administrative. Rather than a discretionary sale, the shares were sold to cover tax withholding obligations tied to the vesting and settlement of restricted stock units, according to the Form 4 filing. In other words, Feeley wasn't actively reducing his investment exposure to GeneDx. The sale was executed through a standard "sell-to-cover" mechanism that many executives use when equity awards vest.
So while insider sales can sometimes raise questions about management's confidence in a business, the filing points to tax planning, not a judgment about the company's prospects.
What's more notable is where GeneDx stands operationally. Shares have fallen roughly 27% over the past year, and the company reported first-quarter revenue of $102.3 million, up 17% year over year but lower than the company had projected, forcing management to update its guidance to call for revenue of up to $490 million this year, down from a top range of $555 million. Nevertheless, CEO Katherine Stueland said demand remains strong and that the company has "never been more confident" in its ability to deliver profitable growth over the long term.
For long-term investors, the filing is probably less important than the underlying business trends. And with expectations now reset and a newly named president, the firm seems like it's positioning itself for a turnaround.
Should you buy stock in GeneDx right now?
Before you buy stock in GeneDx, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and GeneDx wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $393,037!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,280,627!*
Now, it’s worth noting Stock Advisor’s total average return is 913% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of June 23, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
